Promising Experimental Drug Shows Hope for Rare ALS Patients
New data on the antisense oligonucleotide jacifusen (ulefnersen) shows remarkable improvements in two ALS patients with FUS mutations, including functional recovery and disease progression slowing, highlighting potential for early, targeted intervention and ongoing clinical trials.